Welcome to LookChem.com Sign In|Join Free

CAS

  • or

166526-99-4

3-Hydroxy Agomelatine is a metabolite of the synthetic pharmaceutical compound agomelatine, which is primarily used to treat depression. It functions as a potent agonist at melatonin receptors and an antagonist at serotonin receptors, thereby exerting its antidepressant effects. 3-Hydroxy Agomelatine is formed in the body through the metabolism of agomelatine and is believed to contribute to the drug's therapeutic activity. Additionally, it is under investigation for its potential role in treating other conditions such as anxiety and sleep disorders. Further research is necessary to fully comprehend the pharmacological properties and potential applications of 3-Hydroxy Agomelatine.

166526-99-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 166526-99-4 Structure

  • Basic information

    1. Product Name: 3-Hydroxy Agomelatine
    2. Synonyms: 3-Hydroxy Agomelatine
    3. CAS NO:166526-99-4
    4. Molecular Formula: C15H17NO3
    5. Molecular Weight: 259.30038
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 166526-99-4.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 545.8±40.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.190±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 9.85±0.40(Predicted)
    10. CAS DataBase Reference: 3-Hydroxy Agomelatine(CAS DataBase Reference)
    11. NIST Chemistry Reference: 3-Hydroxy Agomelatine(166526-99-4)
    12. EPA Substance Registry System: 3-Hydroxy Agomelatine(166526-99-4)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 166526-99-4(Hazardous Substances Data)

166526-99-4 Usage

Uses

Used in Pharmaceutical Industry:
3-Hydroxy Agomelatine is used as an antidepressant agent for its role in modulating melatonin and serotonin receptors, which contributes to the therapeutic effects of agomelatine in treating depression.
Used in Research and Development:
3-Hydroxy Agomelatine is used as a subject of study for its potential role in the treatment of anxiety and sleep disorders, as well as for understanding its pharmacological properties and exploring additional therapeutic applications.

Check Digit Verification of cas no

The CAS Registry Mumber 166526-99-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,6,5,2 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 166526-99:
(8*1)+(7*6)+(6*6)+(5*5)+(4*2)+(3*6)+(2*9)+(1*9)=164
164 % 10 = 4
So 166526-99-4 is a valid CAS Registry Number.

166526-99-4Upstream product

166526-99-4Relevant articles and documents

Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling

Bogaards, Jan J.P.,Hissink, Erna M.,Briggs, Mike,Weaver, Richard,Jochemsen, Roeline,Jackson, Peter,Bertrand, Marc,Van Bladeren, Peter J.

, p. 117 - 124 (2000)

A strategy is presented to predict interindividual variation in drug plasma levels in vivo by the use of physiologically based pharmacokinetic modeling and human in vitro metabolic parameters, obtained through the combined use of microsomes containing single cytochrome P450 enzymes and a human liver microsome bank. The strategy, applied to the pharmaceutical compound (N-[2-(7-methoxy-1-naphtyl)-ethyl]acetamide), consists of the following steps: (1) estimation of enzyme kinetic parameters K(m) and V(max) for the key cytochrome P450 enzymes using microsomes containing individual P450 enzymes; (2) scaling-up of the V(max) values for each individual cytochrome P450 involved using the ratio between marker substrate activities obtained from the same microsomes containing single P450 enzymes and a human liver microsome bank; (3) incorporation into a physiologically based pharmacokinetic model. For validation, predicted blood plasma levels and pharmacokinetic parameters were compared to those found in human volunteers: both the absolute plasma levels as well as the range in plasma levels were well predicted. Therefore, the presented strategy appears to be promising with respect to the integration of interindividual differences in metabolism and prediction of the possible impact on plasma and tissue concentrations of drugs in humans. Copyright (C) 2000 Elsevier Science B.V.

Naphthalene compounds

-

, (2008/06/13)

Compound of formula (I): wherein: T represents alkylene, A and B together form a naphthalene, dihydronaphthalene, or tetrahydronaphthalene group, R represents hydrogen, hydroxy, R' or OR', R' being as defined in the description, G1 represents halogen, a r

TRISUBSTITUTED NAPHTHYLALKYLAMIDES

-

, (2008/06/13)

The invention relates to a compound selected from those of formula (I) : STR1 in which R, R 1, R 2 and R 3 are as defined in the specification,and a medicinal product containing said compound for treating a disorder of the melatoninergic system.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 166526-99-4